Acellular pertussis vaccines in Japan: Past, present and future

Expert Review of Vaccines

Volumn 4, Issue 2, 2005, Pages 173-184

  Watanabe, Mineo ^a   Nagai, Masaaki ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b KITASATO INSTITUTE   (Japan)

Author keywords

Acellular pertussis vaccine; Adverse reaction; Antivaccine movement; Bordetella parapertussis; Bordetella pertussis; Diagnosis; Surveillance; Whole cell pertussis vaccine; Whooping cough

Indexed keywords

2 PHENOXYETHANOL; 3 DEOXY MANNO OCTULOSONIC ACID; ACELLULAR VACCINE; ADENYLATE CYCLASE TOXIN; ADHESIN; AGGLUTININ; AGGLUTINOGEN 1; AGGLUTINOGEN 2; AGGLUTINOGEN 3; AGGLUTINOGEN 6; ALUMINUM; AMMONIUM SULFATE; BACTERIAL ANTIGEN; BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; CELL RECEPTOR; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; ENDOTOXIN; ETHYLMERCURY DERIVATIVE; FORMALDEHYDE; GELATIN; HEMAGGLUTININ; HYDROGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; INTEGRIN; LIPOOLIGOSACCHARIDE; LIVE VACCINE; MEASLES VACCINE; MERCURY DERIVATIVE; NITROGEN; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PRESERVATIVE; PROTEIN; STABILIZING AGENT; TETANUS TOXOID; THIOMERSAL; UNCLASSIFIED DRUG; URONIC ACID; VIRULENCE FACTOR; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANAPHYLAXIS; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BORDETELLA AVIUM; BORDETELLA BRONCHISEPTICA; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG QUALITY; DRUG SAFETY; DRUG UTILIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; EXPERIMENTAL MODEL; FEVER; GOVERNMENT; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; INFECTION CONTROL; INFECTION SENSITIVITY; INJECTION SITE; JAPAN; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PERTUSSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RASH; REVIEW; RHINORRHEA; RISK BENEFIT ANALYSIS; SKIN INDURATION; SKIN MANIFESTATION; TOXIN ANALYSIS; URTICARIA; VACCINATION; VOMITING;

HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; JAPAN; PERTUSSIS VACCINE; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 17144418504     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.2.173     Document Type: Review

References (65)

1. Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev. Anti-infect Ther. 2(3), 447-454 (2004).
2. Heininger U, Stehr K, Schmitt-Grohe S et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr. Infect. Dis. J. 13(4), 306-309 (1994).
3. Kimura M, Kuno-Sakai H. Developments in pertussis immunisation in Japan. Lancet 336(8706), 30-32(1990).
4. Bordet J, Gengou O. Le microbe de la coqueluche. Ann. Inst. Pasteur 20, 731-741 (1906).
5. Pittman M. Genus Bordetella. In: Bergey's Manual of Systematic Bacteriology. Volume 1. Moreno-Lopez AL (Ed.). Williams and Wilkins, MD, USA, 338-393 (1984).
6. von Wintzingerode F, Schattke A, Siddiqui RA et al. Bordetella petrii sp. nov., isolated from an anaerobic bioreactor, and emended description of the genus Bordetella. Int. J. Syst. Evol. Microbiol. 51, 1257-1295 (2001).
7. Parkhill J, Sebaihia M, Preston A et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. Nature Gen. 35(1), 32-40 (2003).
8. Locht C. Molecular aspects of Bordetella pertussis pathogenesis. Int. Microbiol. 2(3), 137-144 (1999).
9. Parton R. Review of the biology of Bordetella pertussis. Biologicals 27(2), 71-76 (1999).
10. Kerr JR, Preston NW. Current pharmacotherapy of pertussis. Expert Opin. Pharmacother. 2(8), 1275-1282 (2001).
11. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 3(8), 655-677 (2001).
12. McGuirk P, Mills KH. Direct antiinflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur. J. Immunol. 30(2), 415-422 (2000).
13. Robinson A. Acellular and defined-component vaccines against pertussis. In: Pathogenesis and immunity in pertussis. Wardlaw AC, Parton R (Eds.). John Wiley and Sons, Chichester, UK, 399-417 (1988).
14. Jacob-Dubuisson F, Buisine C, Mielcarek N et al. Amino-terminal maturation of the Bordetella pertussis filamentous haemagglutinin. Mol. Microbiol. 19(1), 65-78 (1996).
15. van den Akker WM. The filamentous hemagglutinin of Bordetella parapertussis is the major adhesin in the phase-dependent interaction with NCI-H292 human lung epithelial cells. Biochem. Biophys. Res. Commun. 252(1), 128-133 (1998).
16. Ui M. The multiple biological activities of pertussis toxin. In: Pathogenesis and immunity in pertussis. Wardlaw AC, Parton R (Eds.). John Wiley and Sons, Chichester, UK, 121-145 (1988).
17. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J. Exp. Med. 171(1), 63-73 (1990).
18. Tuomanen E. Bordetella pertussis adhesins. In: Pathogenesis and immunity in pertussis. Wardlaw AC, Parton R (Eds.). John Wiley and Sons, Chichester, UK, 75-94 (1988).
19. Chaby R, Caroff M. Lipopolysaccharides of Bordetella pertussis endotoxin. In: Pathogenesis and immunity in pertussis. Wardlaw AC, Parton R (Eds.). John Wiley and Sons, Chichester, UK, 247-271 (1988).
20. Kuno-Sakai H, Kimura M, Watanabe, H. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Biologicals 32(1), 29-35 (2004).
21. Ministry of Health, Labor, and Welfare. Statistics of communicable diseases in Japan (1998). Ministry of Health, Labor, and Welfare, Tokyo, Japan (1999).
22. Ministry of Health, Labor, and Welfare. Vital Statistics of Japan. Ministry of Health, Labor, and Welfare, Tokyo, Japan (1999).
23. Sato H, Sato Y. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan. Clin. Infect. Dis. 28(Suppl. 2), S124-S130 (1999).
24. Kasuga T. Immunology of pertussis. Keio Igaku 47, 607-627 (1970).
25. Kuno-Sakai H, Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr. Int. 46, 650-656 (2004).
26. CDC. Pertussis. In: Epidemiology and prevention of vaccine-preventable diseases. CDC (Ed.). CDC, Atlanta, USA, 67-83 (2000).
27. Tada Y, Okabe N. Pertussis. Infect. Dis. Wkly Rep. Jpn 5(36), 12-15 (2003).
28. Edward KM, Decker MD. Pertussis vaccine. In: Vaccines. Plotkin SA, Orenstein WA (Eds.). WB Sanders Company, Philadelphia, USA, 471-528 (2004).
29. Griffiths E. Efficacy of whole-cell pertussis vaccine. In: Pathogenesis and immunity in pertussis. Wardlaw AC, Parton R (Eds.). John Wiley and Sons, Chichester, UK, 353-374 (1988).
30. Kimura M, Hikino N. Results with a new DTP vaccine in Japan. Dev. Biol. Stand. 61, 545-561 (1985).
31. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1(8369), 122-126 (1984).
32. Aoyama T, Murase Y, Gonda T, Iwata T. Type-specific efficacy of acellular pertussis vaccine. Am. J. Dis. Child. 142(1), 40-42 (1988).
33. Aoyama T, Murase Y, Kato M, Iwai H, Iwata T. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am. J. Dis. Child. 143(6), 655-659 (1989).
34. Kimura M, Kuno-Sakai H. Current epidemiology of pertussis in Japan. Pediatr. Infect. Dis. J. 9(10), 705-709 (1990).
35. Kimura M, Kuno-Sakai H. Pertussis vaccines in Japan. Acta Paediatr. Jpn 30(2), 143-153 (1988).
36. Kamiya H, Nu R. Overview of currently available Japanese acellular pertussis vaccines and future problems. Tokai J. Exp. Clin. Med. 13(Suppl.), 45-49 (1988).
37. Sato Y, Sato H. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J. Exp. Clin. Med. 13(Suppl.), 79-88 (1988).
38. Sylvia HY. Pertussis; persistant pathogen, imperfect vaccines. Expert Rev. Vaccines 2(1), 113-127 (2003).
39. Horiuchi Y, Takahashi M, Konda T et al. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan. Jpn J. Infect. Dis. 54(5), 167-180 (2001). The authors present brief information regarding quality control of these vaccines in Japan.
40. Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route of challenge. Am. J. Public Health 37, 803-810 (1947).
41. Corbel MJ, Xing DK. Toxicity and potency evaluation of pertussis vaccines. Expert Rev. Vaccines 3(1), 89-101 (2004).
42. Corbel MJ, Xing DK, Kreeftenberg JG. Informal consultation with manufacturers and WHO Ad hoc working group on mouse protection models for acellular pertussis vaccines national institute for biological standards, 12 November 1998. Biolagicals 27(2), 189-193 (1999).
43. Cameron J. Evolution of control testing of pertussis vaccine. In: Pathogenesis and immunity in pertussis. Wardlaw AC, Parton R (Eds.). John Wiley and Sons, Chichester, UK, 419-450 (1988).
44. Xing DK, Das RG, Williams L et al. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 17(6), 565-576 (1999).
45. Watanabe M, Komatsu E, Sato T, Nagai M. Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection. FEMS Immunol. Med. Microbiol. 33(3), 219-225 (2002).
46. Arciniega JL, Corbel M, Dellepiane N et al. WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. Biologicals 26(3), 195-204 (1998).
47. Kreeftenberg JG. Standardization of acellular pertussis vaccines. Biologicals 27(2), 115-117 (1999).
48. Ad Hoc Group for the study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet 1, 955-960 (1988).
49. Kimura M, Hikino N. Result with a new DTP vaccine in Japan. Dev. Biol. Stand. 61, 545-561 (1985).
50. Aoyama T, Murase Y, Kato T, Iwata T. Effecacy of an acellular pertussis vaccine in Japan. J. Pediatr. 107(2), 180-183 (1985).
51. Ministry of Health, Labor, and Welfare. National monitoring on reactogenicity of DTaP vaccines; 1997-2003 (in Japanese). Ministry of Health, Labor, and Welfare, Tokyo, Japan (2004).
52. Yamamoto A, Nagata N, Ochiai M et al. Enhanced sensitisation of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunisation. Vaccine 20(25-26), 3088-3094 (2002).
53. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP - an ultimate solution for vaccine-related gelatin allergy. Biologicals 31(4), 245-249 (2003).
54. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J. Allergy Clin. Immunol. 103(2), 321-325 (1999).
55. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J. Allergy Clin. Immunol. 106(3), 591-592 (2000).
56. Clements CJ. The evidence for the safety of thiomersal in newborn and infant vaccines. Vaccine 22(15-16), 1854-1861 (2004).
57. Hopkins JT. Thiomersal doesn't cause developmental disorders. BMJ 329, 588 (2004).
58. Knezevic I, Griffiths E, Reigel F, Dobbelaer R. Thiomersal in vaccines: a regulatory perspective. WHO Consultation, Geneva, 15-16 April 2002. Vaccine 22(15-16), 1836-1841 (2004).
59. Andreae MC, Freed GL, Katz SL. Safety concerns regarding combination vaccines: the experience in Japan. Vaccine 22(29-30), 3911-3916 (2004). The authors studied issues related to whole-cell vaccines in Japan.
60. Gangarosa EJ, Galazka AM, Wolfe CR et al. Impact of antivaccine movements on pertussis control: the untold story. Lancet 351(9099), 356-361 (1998). The authors summarize the antivaccine movements in several countries and discuss their influence on the public and governments.
61. Fine PE, Clarkson JA. Individual versus public priorities in the determination of optimal vaccination policies. Am. J. Epidemiol. 124(6), 1012-1020 (1986).
62. Crowcroft NS, Britto J. Whooping cough - a continuing problem. BMJ 324(7353), 1537-1538 (2002).
63. He Q, Scmidt-Schlapferg, Just M et al. Impact of polymerase chain reaction on clinical pertussis research; Finnish and Swiss experiences. J. Infect. Dis. 174(6), 1288-1295 (1996).
64. Edelman K, Nikkari S, Ruuskanen O et al. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr. Infect. Dis. J. 15(1), 54-57 (1996).
65. Corbel MJ, Kreeftenberg JG, Knezevic I. WHO Working Group on the standardisation and control of pertussis vaccines - report of a meeting held on 6-7 May 2003, Ferney Voltaire, France. Vaccine 22(3-4), 293-300 (2004).